The global pulmonary function testing market size was estimated at USD 4.12 billion in 2025 and is projected to hit around USD 7.45 billion by 2035, growing at a CAGR of 6.11% during the forecast period from 2026 to 2035.
The pulmonary function testing (PFT) market plays a critical role in the diagnosis, monitoring, and management of respiratory diseases. These tests measure lung capacity, airflow, and gas exchange efficiency, helping clinicians evaluate lung health and detect abnormalities. With the global burden of respiratory diseases increasing significantly, PFT systems have become indispensable tools in modern healthcare.
Chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung diseases are among the leading causes of morbidity and mortality worldwide. Urbanization, air pollution, smoking prevalence, and occupational hazards are key contributors to this rise. For instance, in densely populated urban areas, prolonged exposure to pollutants has led to a surge in asthma and chronic bronchitis cases, thereby increasing the need for regular pulmonary assessments.
Pulmonary function testing is widely used across hospitals, diagnostic laboratories, and outpatient clinics. These tests are not only essential for diagnosing diseases but also for assessing disease progression and evaluating treatment effectiveness. For example, spirometry is routinely used to monitor asthma patients and adjust medication accordingly.
Technological advancements have significantly improved the accuracy and usability of PFT systems. Modern devices are equipped with digital interfaces, real-time data analytics, and connectivity features that allow integration with electronic health records (EHRs). This has enhanced clinical decision-making and patient management.
Furthermore, the COVID-19 pandemic underscored the importance of respiratory health monitoring. Post-COVID complications, including reduced lung capacity and long-term respiratory impairment, have increased the demand for pulmonary testing. This has created a sustained need for PFT systems in both clinical and home settings.
Artificial Intelligence (AI) is playing a transformative role in the pulmonary function testing market by enhancing diagnostic accuracy, automating workflows, and enabling predictive healthcare.
AI-powered algorithms can analyze spirometry and other PFT data with high precision, identifying patterns that may not be easily detectable by human interpretation. For instance, AI can differentiate between obstructive and restrictive lung diseases by analyzing airflow curves and lung volumes. This reduces diagnostic errors and ensures early detection of conditions such as COPD.
In clinical settings, AI integration helps automate report generation and interpretation. Instead of manually analyzing test results, clinicians can rely on AI-driven systems to provide instant insights and recommendations. This is particularly beneficial in high-volume hospitals where time efficiency is critical.
Another significant application of AI is in remote monitoring. Portable PFT devices integrated with AI can track patient data in real time and alert healthcare providers to any abnormalities. For example, asthma patients using home spirometry devices can receive early warnings of exacerbations, enabling timely intervention.
AI is also enabling predictive analytics in respiratory care. By analyzing historical patient data, AI models can predict disease progression and hospitalization risks. This allows healthcare providers to implement preventive measures, improving patient outcomes and reducing healthcare costs.
| Report Coverage | Details |
| Market Size in 2026 | USD 4.37 Billion |
| Market Size by 2035 | USD 7.45 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 6.11% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Type, Test Type, Component, Application, End User, Region |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | COSMED srl, Vyaire Medical, Inc, Schiller, Medical Equipment Europe GmbH, Medical Electronic Construction, ECO MEDICS AG, CHEST M.I., Inc, MGC Diagnostic Corporation, and Medical Technologies |
How did the complete PFT systems segment dominate the Global Pulmonary Function Testing market?
The complete PFT systems segment is driven by the urgent need to manage surging patient volumes for asthma and COPD. These integrated platforms offer all-in-one diagnostic capabilities, such as plethysmography and gas analysis, that are essential for accurately assessing complex respiratory illnesses. Enhanced by advanced digital connectivity and superior accuracy, complete systems remain the clinical standard over smaller devices.
How did the portable PFT systems segment expect to hold the fastest-growing Global Pulmonary Function Testing market in the coming years?
The portable PFT systems segment is driven by the transition toward decentralized care is accelerating the global adoption of portable PFT systems, empowering patients with remote and home-based respiratory monitoring. Enhanced by Bluetooth and cloud connectivity, these devices allow for seamless data sharing and improved diagnostic accuracy via AI-driven analytics. Their compact design has significantly increased accessibility within small clinics and independent centers, providing a cost-effective alternative to stationary units.
How did the spirometry segment account for the largest share in the Global Pulmonary Function Testing market?
The spirometry segment is driven by the integration of wireless and smart devices is revolutionizing the segment by delivering lab-grade accuracy in convenient, portable formats suitable for both clinics and home monitoring. This technological shift is particularly critical for the aging population, who require frequent and accessible screening to manage chronic lung conditions. The transition to digitalized, handheld solutions ensures that spirometry continues to dominate the market through enhanced reliability and patient ease of use.
How did the lung volume segment expect to hold the fastest-growing Global Pulmonary Function Testing market in the coming years?
The lung volume segment is driven by the critical need for precise lung volume measurements to assess disease severity. Modern advancements in body plethysmography have significantly improved the accuracy of calculating residual volume, offering a level of detail that standard spirometry cannot provide. This shift toward comprehensive patient evaluation makes lung volume testing an essential component of the diagnostic process in advanced respiratory care.
How did the hardware segment account for the largest share in the Global Pulmonary Function Testing market?
The hardware segment is driven by the innovation in compact and user-friendly devices is bridging the gap between hospital-grade accuracy and the growing demand for portable occupational and home care solutions. The continuous advancement of these tools ensures a robust infrastructure for the routine monitoring and early detection of industrial and chronic lung diseases.
How did the services segment expect to hold the fastest-growing Global Pulmonary Function Testing market in the coming years?
The services segment is driven by the integration of cloud-based analytics is transforming the sector, enabling real-time data interpretation and secure storage as remote and home-based monitoring becomes more prevalent. The heightened focus on preventative maintenance ensures that point-of-care diagnostics remain accurate and reliable, fulfilling the strict regulatory requirements of modern respiratory care.
How did the chronic obstructive pulmonary diseases segment account for the largest share in the Global Pulmonary Function Testing market?
The chronic obstructive pulmonary diseases segment is driven by the aging population and rising environmental hazards, necessitating more frequent diagnostic interventions and post-operative assessments. The integration of IoT-enabled smart devices and rapid testing hardware is revolutionizing how these chronic conditions are monitored, shifting care toward more efficient, data-driven solutions. As routine testing becomes a critical pillar of respiratory healthcare, the market is expanding to accommodate the high-volume needs of both hospitals and decentralized clinics.
How did the restrictive lung diseases segment expect to hold the fastest-growing Global Pulmonary Function Testing market in the coming years?
The restrictive lung diseases segment is driven by the escalating global prevalence of intestinal lung diseases and fibrosis is driving a critical need for high-precision diagnostics tools to monitor declining lung functionality. Technological breakthroughs in advanced plethysmography have significantly enhanced the accuracy of identifying restrictive patterns that traditional spirometry may overlook. This demand is further amplified by a growing geriatric population and proactive early diagnosis initiatives, particularly in occupational health settings.
How did the hospital/clinical laboratory segment account for the largest share in the Global Pulmonary Function Testing market?
The hospital/clinical laboratory segment is driven by the significant investment in sophisticated PFT infrastructure, including advanced plethysmography, allows for high-precision diagnostics that smaller facilities cannot replicate. By offering integrated clinical services, hospitals provide a comprehensive diagnostic pathway that combines lung function testing with imaging and laboratory analysis. This concentration of advanced technology and medical expertise ensures that hospitals remain the critical hub for the standardized management of COPD, asthma, and fibrosis.
How did the diagnostics laboratories segment expect to hold the fastest-growing Global Pulmonary Function Testing market in the coming years?
The diagnostics laboratories segment is driven by the integration of AI-assisted interpretation and digital spirometry is significantly enhancing accuracy for complex assessments, such as gas diffusion and lung volume. The shift toward decentralized care, where portable devices enable high-quality respiratory diagnostics in regional and community settings. As emerging markets in the Asia-Pacific build out their diagnostic infrastructure, these labs are becoming the primary engines for the early detection and management of chronic lung diseases.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the pulmonary function testing market.
By Type
By Test Type
By Component
By Application
By End User
By Region
Pulmonary Function Testing Market
Download Sample
Request Customization
Request Customization
Download Sample